Gene polymorphism of patients with type 2 diabetes mellitus in combination with non-alcoholic fatty liver disease
AbstractThe course of type 2 diabetes mellitus (T2DM) is often associated with various diseases affecting organs and systems of the body such as cardiovascular, reproductive, hepatobiliary systems, etc. The subject of our study is non-alcoholic fatty liver disease, since both of these diseases have many common pathogenetic elements as well as genetically individualized risks of occurrence. The presented studies allow a deeper understanding of genetically individualized risks, which will contribute to more effective therapeutic practice.
The objective of research is to analyze actual literature data, whose research subject is the treatment of T2DM in conjunction with non-alcoholic fatty liver disease in order to study the polymorphism of genes that determine the development of these diseases.
Material and methods. In writing this review were used clinical records based on foreign and domestic studies. In order to find the literature data were used resources such as PubMed, Willey, eLIBRARY, Web of Science, Lancet.
Results. In the review are presented the current views on the diagnosis, treatment and the assessment of the disease's severity and the following therapy of T2DM in combination with non-alcoholic fatty liver disease taking into account genetically individualized risks as well as was analyzed the tactics of therapy for this group of patients.
Conclusion. The result of the current domestic and foreign publications review is the confirmation of the importance of adequate patient`s therapy with T2DM in combination with non-alcoholic fatty liver disease. The problem of genetically individualized risks is an active subject of research, which makes it possible to expect fundamentally new pharmacological methods of management of this category of patients.
Keywords:type 2 diabetes mellitus; non-alcoholic fatty liver disease; gene polymorphism; PNPLA3 gene; GCKR gene; MBOAT7 gene; TMC 4 gene; TM6SF2 gene
Funding. The study had no sponsor support.
Conflict of interest. The authors declare no conflict of interest.
For citation: Vorobyev S.V., Ivanova A.A., Rasskazova M.A., Slyusarenko D.A. Gene polymorphism of patients with type 2 diabetes mellitus in combination with non-alcoholic fatty liver disease. Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2023; 12 (1): 33–8. DOI: https://doi.org/10.33029/2304-9529-2023-12-1-33-38 (in Russian)
References
1. Galicia-Garcia U., Benito-Vicente A., Jebari S., Larrea-Sebal A., Siddiqi H., Uribe K.B., et al. Pathophysiology of type 2 diabetes mellitus. Int J Mol Sci. 2020; 21: 6275.
2. Leoni S., Tovoli F., Napoli L., Serio I., Ferri S., Bolondi L. Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis. World J Gastroenterol. 2018; 24 (30): 3361–73.
3. Perumpail B.J., Khan M.A., Yoo E.R., Cholankeril G., Kim D., Ahmed A. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J Gastroenterol. 2017; 23: 8263–76.
4. Chazova I.E., et al. Guidelines for the treatment of patients with metabolic syndrome. Clinical recommendations of the Ministry of Health of Russia. Cardiol J. 2013; 1: 3–57.
5. Rinella M.E. Nonalcoholic fatty liver disease: A systematic review. JAMA. 2015; 313: 2263–73. DOI: https://doi.org/10.1001/jama.2015.5370
6. Sepanlou S.G., Safiri S., Bisignano C., Ikuta K.S., Merat S., Saberifiroozi M., et al. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study. Lancet Gastroenterol Hepatol. 2020; 5: 245–66. DOI: https://doi.org/10.1016/S 2468-1253(19)30349-8
7. Loomba R., Abraham M., Unalp A., Wilson L., Lavine J., Doo E., et al.; Nonalcoholic Steatohepatitis Clinical Research Network. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology. 2012; 56: 943–51.
8. Ivashkin V., Drapkina O. The prevalence of non-alcoholic fatty liver disease in Russian Federation. Gut. 2009; 58: 1207.
9. Bril F., Cusi K. Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: A call to action. Diabetes Care. 2017; 40: 419–30.
10. Han E., Lee Y.H. Non-alcoholic fatty liver disease: the emerging burden in cardiometabolic and renal diseases. Diabetes Metab J. 2017; 41: 430–7.
11. Chalasani N., Younossi Z., Lavine J.E., Charlton M., Cusi K., Rinella M., et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018; 67: 328–57.
12. Ekstedt M., Hagström H., Nasr P., Fredrikson M., Stal P., Kechagias S., et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015; 61: 1547–54.
13. Younossi Z.M., Koenig A.B., Abdelatif D., Fazel Y., Henry L., Wymer M. Global epidemiology of nonalcoholic fatty liver disease–meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016; 64: 73–84.
14. Morling J.R., Fallowfield J.A., Guha I.N., Nee L.D., Glancy S., Williamson R.M., et al.; Edinburgh Type 2 Diabetes Study Investigators. Using non-invasive biomarkers to identify hepatic fibrosis in people with type 2 diabetes mellitus: the Edinburgh type 2 diabetes study. Hepatology. 2014; 60: 384–91.
15. Romeo S., Kozlitina J., Xing C. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008; 40: 1461–5. DOI: https://doi.org/10.1038/ng.257
16. Saki S., Saki N., Poustchi H., Malekzadeh R. Assessment of genetic aspects of non-alcoholic fatty liver and premature cardiovascular events. Middle East J Dig Dis. 2020; 12: 65–88.
17. Tikhomirova A.S., Kislyakov V.A., Baykova I.E., et al. Clinical-morphological parallels of the PNPLA3 gene polymorphism in patients with nonalcoholic fatty liver disease. Ther. Arch. 2018; 90: 85–8.
18. Wang Y., Kory N., Cohen J.C., Hobbs H.H PNPLA3, CGI-58, and inhibition of hepatic triglyceride hydrolysis in mice. Hepatology. 2019; 69: 2427–41.
19. Yang A., Mottillo E.P., Mladenovic-Lucas L., Zhou L., Granneman J.G. Dynamic interactions of ABHD 5 with PNPLA3 regulate triacylglycerol metabolism in brown adipocytes. Nat Metab. 2019; 1; 560–9.
20. Negoita F., Blomdahl J., Wasserstrom S., Winberg M.E., Osmark P., Larsson S., et al. PNPLA3 variantM148 causes resistance to starvation-mediated lipid droplet autophagy in human hepatocytes. J Cell Biochem. 2019; 120: 343–56. DOI: https://doi.org/10.1002/jcb.27378
21. Lazebnik L.B., Radchenko V.G., Golovanova E.V., Zvenigorodskaya L.A., et al. Nonalcoholic fatty liver disease: clinic, diagnosis, treatment (recommendations for therapists, 2-version). Exp Clin Gastroenterol. 2017; 138: 22–37.
22. Van Schaftingen E. A protein from rat liver confers to glucokinase the property of being antagonistically regulated by fructose 6-phosphate and fructose 1-phosphate. Eur J Biochem. 1989; 179: 179–84.
23. Tan H.-L., Zain S.M., Mohamed R., et al. Association of glucokinase regulatory gene polymorphisms with risk and severity of non-alcoholic fatty liver disease: An interaction study with adiponutrin gene. J Gastroenterol. 2014; 49; 1056–64.
24. Zahedi A.S., Akbarzadeh M., Sedaghati-Khayat B., Seyedhamzehzadeh A., Daneshpour M.S. GCKR common functional polymorphisms are associated with metabolic syndrome and its components: A 10-year retrospective cohort study in Iranian adults. Diabetol Metab Syndr. 2021; 13: 20.
25. Buch S., Stickel F., Trépo E., et al. A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis. Nat Genet. 2015; 47: 1443–48. DOI: https://doi.org/10.1038/ng.3417
26. Thabet K., Asimakopoulos A., Shojaei M., et al. MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C. Nat Commun. 2016; 7: 12757. DOI: https://doi.org/10.1038/ncomms12757
27. Mancina R.M., Dongiovanni P., Petta S., et al. The MBOAT7-TMC 4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent. Gastroenterology. 2016; 150: 1219–30. DOI: https://doi.org/10.1053/j.gastro.2016.01.032
28. Carim-Todd L., Escarceller M., Estivill X., Sumoy L. Cloning of the novel gene TM6SF1 reveals conservation of clusters of paralogous genes between human chromosomes 15q24–>q26 and 19p13.3–>p12. Cytogenet Cell Genet. 2000; 90: 255–60.
29. Kozlitina J., Smagris E., Stender S., Nordestgaard B.G., Zhou H.H., Tybjærg-Hansen A., et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2014; 46: 352–6.
30. Mahdessian H., Taxiarchis A., Popov S., Silveira A., Franco-Cereceda A., Hamsten A., et al. TM6SF2 is a regulator of liver fat metabolism influencing triglyceride secretion and hepatic lipid droplet content. Proc Natl Acad Sci USA. 2014; 111: 8913–8.
31. Holmen O.L., Zhang H.E., Fan Y., Hovelson D.H., Schmidt E.M., Zhou W., et al. Systematic evaluation of coding variation identifies a candidate causal variant in TM6SF2 influencing total cholesterol and myocardial infarction risk. Nat Genet. 2014; 46: 345–51.
32. Matsuba R., Sakai K., Imamura M., Tanaka Y., Iwata M., Hirose H., et al. Replication study in a Japanese population to evaluate the association between 10 SNP loci, identified in European genome-wide association studies, and type 2 diabetes. PLoS One. 2015; 10 (5): e01216363. DOI: https://doi.org/10.1371/journal.pone.0126363 PMID: 25951451; PMCID: PMC 4423838.
33. Zhou Y., Llauradó G., Orešič M., Hyötyläinen T., Orho-Melander M., Yki-Järvinen H. Circulating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E 167K variant in TM6SF2. J Hepatol. 2015; 62 (3): 651–63. DOI: https://doi.org/10.1016/j.jhep.2014.10.010 Epub 2014 Oct 19. PMID: 25457209.
34. Mancina R.M., Sentinelli F., Incani M., Bertoccini L., Russo C., Romeo S., et al. Transmembrane-6 superfamily member 2 (TM6SF2) E 167K variant increases susceptibility to hepatic steatosis in obese children. Dig Liver Dis. 2016; 48: 100–1.
35. Grandone A., Cozzolino D., Marzuillo P., Cirillo G., Di Sessa A., Ruggiero L., et al. TM6SF2 Glu167Lys polymorphism is associated with low levels of LDL-cholesterol and increased liver injury in obese children. Pediatr Obes. 2016; 11: 115–9.
36. Zhou Y., Llauradó G., Orešič M., Hyötyläinen T., Orho-Melander M., Yki-Järvinen H. Circulating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E 167K variant in TM6SF2. J Hepatol. 2015; 62: 657–63.
37. Liu Y.-L., Reeves H.L., Burt A.D., Tiniakos D., McPherson S., Leathart J.B.S., et al. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nat Commun. 2014; 5: 4309.
38. Pirola C.J., Sookoian S. The dual and opposite role of the TM6SF2-rs58542926 variant in protecting against cardiovascular disease and conferring risk for nonalcoholic fatty liver: A meta-analysis. Hepatology. 2015; 62: 1742–56.
39. Holmen O.L., Zhang H.E., Fan Y., Hovelson D.H., Schmidt E.M., Zhou W., et al. Systematic evaluation of coding variation identifies a candidate causal variant in TM6SF2 influencing total cholesterol and myocardial infarction risk. Nat Genet. 2014; 46: 345–51.
40. Dongiovanni P., Petta S., Maglio C., Fracanzani A.L., Pipitone R., Mozzi E., et al. Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology. 2015; 61: 506–14.